#JPM22: The fire­side chat with Take­da CEO Christophe We­ber

John Car­roll:

Okay every­body. This is John Car­roll. I am back with Christophe We­ber, the CEO of Take­da. We had a chance to talk I think about a year ago, about the com­pa­ny and every­thing. In a lot of dif­fer­ent re­spects Christophe, this is kind of a key in­flec­tion point, I think for Take­da in terms of where you are at right now. You got the CEO job. You were charged with chang­ing the cul­ture, rather dra­mat­i­cal­ly, and chang­ing the di­rec­tion and fo­cus­ing in on R&D. And you have been I think, very fo­cused on R&D, very fo­cused on in­no­va­tion. To­wards the lat­ter part of last year, you had a cou­ple of key drug ap­provals. I don’t know if I can pro­nounce this prop­er­ly. One was Exkiv­i­ty and the oth­er was Liv­tenci­ty, which sound like cousins. I don’t know where you guys come up with these names. It sounds like they’re beamed in. Where do these names come from?

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER